A landmark milestone in access for MGD care
The TearCare® system is now reimbursed in the Novitas and First Coast Medicare MAC jurisdictions.
The TearCare® System, an interventional therapy that targets the leading cause of dry eye disease by directly treating Meibomian Gland Disease (MGD), has reached a significant milestone with an established fee schedule from Novitas and First Coast. This coverage helps remove a critical barrier to effective dry eye care and could greatly improve patient access to this clinically proven treatment.1-3
Turning Access into Care
- Millions of patients now have reimbursed access to in-office MGD therapy
- Improves patient access to a therapy proven clinically superior to leading dry eye prescription1-3
- Reduces a barrier tied to patient eye drop compliance
Left to right: Dr. Cecella Koetting, Dr. Brandon Ayres, Dr. Walter Whitley, Dr. Neel Desai, Dr. Mina Farahani
Your support helped us achieve this win!
But let’s keep going – together, we can deliver on the commitment to redefine what fair, accessible, and effective MGD care looks like.
The TearCare® System is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomain gland dysfunction (MGD), when used in conjunction with manual expression of the maibomain glands.
Please see instructions for Use or visit TearCare.com for Contraindications, Warnings, Precautions and Adverse Events.
TearCare, SmartLids, SmartHub, and Clearance Assistant, are trademarks or registered trademarks of Sight Sciences, Inc.
All other trademarks are the property of their respective owners.
References: 1. Ayres BD, et al. Clin Ophthalmol. 2023 Dec 18;17:3925-3940. 2. Ayres BD, et al. Clin Ophthalmol. 2024 May 28;18:1525-1534. 3. Hovanesian J, et al. Optom Vis Sci.
2025 Aug;102(8):p 495-504.
At 6 months TearCare demonstrated superiority to Restasis® for the improvement of tear break up time, the trial's primary dry eye signs endpoint. At 6 months TearCare® and Restasis® both demonstrated comparable statistically significant improvements at all time points measured for dry eye symptoms.
© 2025 Sight Sciences, Inc. 10/25 TC-2382-US.v4
Sight Sciences, the Sight Sciences logo, and TearCare are registered trademarks of Sight Sciences, Inc.